


## CLAIMS

1. An oxygen infusion for increasing an oxygen concentration in tumor tissues in living bodies, said oxygen infusion comprising a dispersion of an albumin clathrate compound including porphyrin metal complex, dispersed in a physiologically permissible aqueous media.
- 5 2. The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex represented by the general formula (I):

10 [Chem. 7]

General formula (I)




[wherein R<sub>1</sub> is a chain or alicyclic hydrocarbon group that may have one or more substituents,

R<sub>2</sub> is a basic axial ligand expressed by the formula (A) :

[chem. 8]


Formula (A)



(where R3 is alkylene, R4 is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M), or a basic axial ligand represented by the formula (B):

5 [Chem. 9]

Formula (B)




(where R5 is alkylene, R6 is alkyl); and

M is a transition metal ion of the 4th or 5th period of the periodic table of elements], and/or a porphyrin metal complex represented by the general formula [II]:

10 [Chem. 10]

General formula (II)



[wherein R7 is a chain or alicyclic hydrocarbon group that may have one or more substituents,


R8 is alkyloxy, alkylamino, amino or an amino acid derivative residue,

5 R9 is an basic axial ligand represented by the formula

[C]:

[Chem. 11]


Formula (C)



(where R10 is alkylene, R11 is a group that does not inhibit coordination of said basic axial ligand to a  
10 central transition metal ion M), or an basic axial ligand represented by the formula (D):

[Chem. 12]

Formula (D)



(where R<sub>12</sub> is alkyl), and

M is a transition metal ion of the 4th or 5th period of the periodic table of elements].

3. The oxygen infusion according to claim 2, wherein  
 5 said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R<sub>1</sub> is C<sub>1</sub>-C<sub>19</sub> chain hydrocarbon group having dimethyl groups at the first position or C<sub>3</sub>-C<sub>19</sub> alicyclic hydrocarbon having a substituent at the first position, R<sub>3</sub> is C<sub>1</sub>-C<sub>10</sub> alkylene,  
 10 R<sub>4</sub> is hydrogen, methyl, ethyl or propyl, R<sub>5</sub> is C<sub>1</sub>-C<sub>10</sub> alkylene, R<sub>6</sub> is C<sub>1</sub>-C<sub>18</sub> alkyl, M is Fe or Co.

4. The oxygen infusion according to claim 2, wherein  
 15 said porphyrin metal complex is a porphyrin metal complex of the general formula (II), in which R<sub>7</sub> is hydrogen, vinyl, ethyl or methoxy; R<sub>8</sub> is C<sub>1</sub>-C<sub>18</sub> alkyloxy, C<sub>1</sub>-C<sub>18</sub> alkylamino, amino acid or a derivative residue thereof; R<sub>10</sub> is C<sub>1</sub>-C<sub>10</sub> alkylene; R<sub>11</sub> is hydrogen, methyl, ethyl or propyl; R<sub>12</sub> is C<sub>1</sub>-C<sub>18</sub> alkyl; and M is Fe or Co.